Alto Neuroscience, Inc.

NYSE:ANRO

Biotechnology

Healthcare
$25.91 +1.84%

+$0.40 today

Market cap
$1.04B
Beta
1.25
P/E (TTM)
-9.8
EPS (TTM)
-$2.26
52W Low $2.15High $28.44

Volume 0.99M

Average 0.34M

ANRO Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Alto Neuroscience, Inc.NYSE: ANRO

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $6.84M rose 20.0% year over year, ahead of the -3.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 35.3% from the prior quarter. Over 3 fiscal years it compounded at +59.0% a year.

Context

  • Selling, general & admin increased in 2 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -4.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.84M+35.3% QoQ
Last fiscal yearDec 2025
$20.75M-4.0% YoY
LTMMar 2026
$21.89M-3.6% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.0%-100.0%-120.0 pp
1 year-4.0%-100.0%-96.0 pp
3-year CAGR+59.0%+9.3%-49.7 pp
5-year CAGR+113.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
20.75M USD
Year-over-year change
-4.0%
4-year CAGR
+53.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ANRO compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -3.6% is the 8th highest of 10, against a peer median of +13.5%.
  • Over three fiscal years its annual growth of +59.0% compares with a peer median of +4.5%.
ANRO Competitors
Selling, General & Admin for ANRO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$1.14T USD+9732467.6%-14.5%—
AMRNAmarin Corporation plcLTM Mar 2026$99.54M USD-33.2%-27.7%46.3%
DBVTDBV Technologies S.A.LTM Mar 2026$38.19M USD+65.9%+17.2%—
KRROKorro Bio, Inc.LTM Mar 2026$30.49M USD-15.8%+18.8%793.5%
SLNSilence Therapeutics plcLTM Mar 2026$23.59M USD—+2.2%2560.2%
ANROAlto Neuroscience, Inc.LTM Mar 2026$21.89M USD-3.6%+59.0%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$19.82M USD+7.4%+14.2%—
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$17.4M USD+18.2%+41.6%—
ACIUAC Immune S.A.LTM Mar 2026CHF 11.38M CHF+4.4%+6.7%307.5%
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$10.42M USD+13.5%-3.1%—
CLLSCellectis S.A.LTM Mar 2026$9.18M USD+20.3%-1.1%13.5%
Peer median (excluding ANRO) —+13.5%+4.5%307.5%

Competitors are the stored peer set for ANRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue210K0000
Cost of Revenue145K342K0502K661K
Gross Profit65K(342K)0(502K)(661K)
Gross Margin31.0%————
Research & Development8.37M23.69M30.29M47M45.62M
Selling, General & Admin3.75M5.16M7.52M21.61M20.75M
Operating Expenses12.12M28.85M37.81M68.11M65.7M
Depreciation & Amortization145K342K373K502K661K
EBITDA(9.04M)(27.37M)(34.56M)(62.3M)(60.11M)
EBITDA Margin-4305.7%————
Operating Income(12.06M)(29.19M)(37.81M)(68.61M)(66.36M)
Operating Margin-5741.0%————
Interest Income2K114K2.35M8.85M6.6M
Interest Expense001.37M(1.38M)2.47M
Other Income / Expenses2.87M1.48M1.5M7.18M3.13M
Income Before Tax(9.19M)(27.71M)(36.31M)(61.43M)(63.24M)
Pre-Tax Margin-4374.8%————
Income Tax Expense00000
Net Income(9.19M)(27.71M)(36.31M)(61.43M)(63.24M)
Net Margin-4374.8%————
EPS (Basic)(0.36)(1.08)(1.35)(2.50)(2.19)
EPS (Diluted)(0.36)(1.08)(1.35)(2.50)(2.19)
Weighted Avg Shares25.57M25.57M26.88M24.6M28.85M
Weighted Avg Shares (Diluted)25.57M25.57M26.88M24.6M28.85M

Alto Neuroscience, Inc.

NYSE:ANRO

Intrinsic Alpha fair value

Locked

Current Price

$25.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.